This is newest discovery in the field of Nano-medicine.
Indeed, in recent years, nanoparticles have proven their worth in delivering potent cancer drugs directly to the site of the tumor, allowing doctors to minimize the often dangerous side effects of chemotherapy. According to the National Cancer Institute, the field of nanomedicine grew exponentially from 2000 to 2010, and the agency predicts that the United States workforce in nanomedicine will reach 2 million by 2015. Our focus is to make use of existing nanotechnology concept, and to take that model to next level of its potential. Lots of progress has been made in this area and there is a lot more left to discover. What has been accomplished is the use of various possible means to make various drugs into nano particles. Rrecent developments are to use these nanomedicines in combination with other drugs, small or large molecules. Nanomedicine is still a very young field within the broader scope of pharmaceuticals-Abraxis BioScience's (now Celgene's) Abraxane and Janssen's Doxil are some of the big names that have paved the way with FDA approval. But where nanotech is really booming at the moment is in pre and early-stage clinical trials, where scientists are discovering new applications that could ultimately lead to the next big blockbuster.
With high-profile entrepreneurs like Robert Langer and well-known entities such as MIT and the National Institutes of Health investing in the innovation side of nanotech, the field is growing at a rapid pace. And the best part about it, analysts say, is that by focusing on the delivery of tried-and-true drugs, there's a relatively low overhead compared to the benefit the platforms provide in much-needed areas like cancer and diabetes. And new nanomeds are showing more than ever that they can improve those treatments with controlled, targeted delivery.
This notion of nanomedicine and its applications caused us to think a bit "out of the box" about routine nanoparticle generation using regular means, and this conviction gave birth to a new concept of Hybrid drugs as solubility solution for insoluble drugs discovered by Dr. Mewa Singh, a HYBRID-NANOENGINEERINGTM platform, could have a real therapeutic value for patients. That belief gave birth to a process of continual discovery and innovation, allowing it to bring many innovative medicines and formulations (over 80 drugs).
We have been working to commercialize a technology that could have a significant impact with cancer, pain and inflammation; making treatment more effective and less harmful to patients. The application is huge and we cannot afford to shoulder the entire responsibility at this stage of our growth. So we picked few and Docetaxel is one of them. Docetaxel is a clinically well-established anti-mitotic chemotherapy medication. It is used mainly for the treatment of breast, ovarian, prostate, and non-small cell lung cancer. Docetaxel has an FDA approved claim for treatment of patients who have locally advanced, or metastatic breast or non-small-cell lung cancer who have undergone anthracycline-based chemotherapy and failed to stop cancer progression or relapsed and a European approval for use in hormone-refractory prostate cancer.
Inspite of its potential docetaxel has been associated with a significant increase in neutropenia, febrile neutropenia, leucopenia, stomatitis, edema, fatigue and/or asthenia, and diarrhea. These effects are due in part to the high doses used to achieve the desired anti-tumor effect, which are necessary because of the non-specific distribution of both novel and traditional chemotherapies, with only a small fraction of drugs reaching the tumor. It is well known that injected materials suffer from sequestration by the reticuloendothelial system, which is composed of monocytes and macrophages that clear foreign materials. The drugs can accumulate in healthy organs, and there is a fine line between tolerability and severe morbidity, e.g., in the case of doxorubicin, a DNA intercalator that produces cardiotoxicity. Moreover, the commercial formulation of docetaxel, TaxotereR, is formulated with a high concentration of Tween 80 (40 g/L), which has been found to have severe side effects, including hypersensitivity reactions, cumulative fluid retention, and nausea and which has shown incompatibility with commonly used polyvinyl chloride intravenous administration sets. Taken together, these factors compromise the curative potential of anticancer drugs, and more effective methods for their delivery to tumors are required.
Our technology took care of these limitations and made an advancement in this drug by using our technology platform, which not only will enhance the bioavailability but also improve the efficacy of the drugalleviate the unnecessary toxicity of the inactive carriers, like tween-80, alcohol, or other oils. In fact it is a new treatment.
If you are interested in funding our projects, please contact us.